Latest News - Nicox

Tuesday, April 19, 2016 | Nicox

Nicox Submits New Drug Application to FDA for Allergic Conjunctivitis Eye Drug Candidate

Nicox announced the submission of a new drug application (NDA) to the FDA for approval of AC-170, its novel, proprietary, cetirizine eye drop formulation, for the treatment of ocular itching asso…

Read the full story

Friday, January 29, 2016 | Partnerships, Nicox

Nicox Out-Licenses OTC Morning Eyelid Swelling Drug Candidate to Ora Inc.

Nicox SA and Ora Inc. announced that Nicox's subsidiary, Nicox Ophthalmics, and Ora entered into a license agreement granting Ora exclusive worldwide rights for the development and commercializati…

Read the full story

Tuesday, September 22, 2015 | Glaucoma, Bausch+Lomb, Nicox

Bausch + Lomb and Nicox Announce FDA Acceptance of New Drug Application for Glaucoma Candidate Vesneo

Bausch + Lomb and Nicox SA announced that the FDA has accepted for review its new drug application (NDA) for Vesneo (latanoprostene bunod 0.024%), an IOP-lowering single-agent eye drop dosed once dail…

Read the full story

Wednesday, June 03, 2015 | Earnings & Financials, Nicox

Nicox Provides Updates on its Ophthalmic Pipeline

Nicox SA provided updates on its lead clinical candidates Vesneo and AC-170, both on track for new drug application (NDA) submission with the FDA, according to a company news release. Nicox's l…

Read the full story

Monday, February 02, 2015 | Acquisitions/Mergers, Nicox

InSite Vision Announces License Agreement for AzaSite, AzaSite Xtra, and BromSite in Europe, Middle East, and Africa

InSite Vision announced that it has entered into a license agreement with Nicox SA for the development and commercialization of InSite’s ophthalmic therapeutic products AzaSite (1% azithromycin)…

Read the full story